第十九届深圳国际金融博览会暨2025中国金融机构年会日前在深圳举行。在"中国银行业年会"分论坛上，阳光保险集团首席经济学家邱晓华发表题为"中国经济 分析与展望"的主题演讲。 邱晓华指出，过去一年，中国经济顶住了复杂的外部压力，以及内部转型升级的阵痛，在风浪中实现了稳中有进的发展，全年有望实现年初制定的5%左右的GDP增 长目标。 他认为，这份成绩单背后对应四个关键因素：宏观政策积极有为；深化改革和扩大开放持续释放制度红利；消费继续发挥"压舱石"作用；外部冲击的时效性特征使 进出口波动得到缓冲。 展望未来，邱晓华从经济周期、科技革命与地缘政治三个维度进行了深刻剖析。他表示，虽然前行路上仍面临挑战，但中国经济正在积蓄新的发展动能，未来发展 前景值得期待。 自身周期视角：第四次经济调整接近尾声 从中国经济自身的发展周期回顾，改革开放以来的历程并非一帆风顺，而是经历了数次起落调整。 邱晓华在演讲中清晰地梳理了前三个主要周期：80年代末的价格改革闯关、90年代末的亚洲金融危机以及2008年的国际金融危机，每一次中国经济都通过政策的优 化和改革开放的深化，成功走出了困境，并迈上了新的发展台阶。 他认为，当前中国经济正处在 ...

扬子晚报网讯（记者 朱亚运）11月24日上午，2025健康中国建设大会暨长三角智慧康养嘉年华活动在 南通开幕。本次活动以"数智创新服务银发，融汇共创健康中国"为主题，既搭建高端学术研讨的专业平 台，又打造了贴近民生的健康体验场景，推动数智技术和大健康老龄健康领域的深度融合，将为健康中 国建设注入强劲的长三角动能。 开幕式上，国家及省市相关部委领导、两院院士、国内大型三甲医院院长专家、知名企业负责人等各界 代表参加。南通市人民政府与健康报社战略合作协议签，崇川区人民政府、南通市民政局、南通市医保 局与通用技术康养公司战略合作协议的签约仪式；一批生物医药项目集中签约。随后，各路专家学者将 集中展现健康科技领域的前沿创新成果。 南通，作为著名的"长寿之乡"和长三角北翼的经济重镇，不仅在经济发展上活力迸发，更在康养事业领 域有着深厚的底蕴与积极的探索。 与此同时，南通康养产业基础实、潜力大。德国默克、拜耳、瑞士斯福瑞等国际知名企业长期深耕，澳 斯康、精华制药（002349）等本土领军企业培育壮大，北大生命科学华东产研院、复旦张江医学研究院 等科创平台加快布局，启东开发区、海门临江新区、市北高新（600604）区、紫琅 ...

以下文章来源于城市战争 ，作者孙不熟 城市战争 . 趁稿子不注意的时候，把它写出来。 编者荐语： 因为今年有苏超？ 高手过招，胜负往往在毫厘之间。 三季度经济数据出炉，经济大省你追我赶，精彩纷呈。例如广东与江苏、山东与浙江、四川与河南、湖北与福建其实都在伯仲之间，谁超过谁都不奇 怪。 以下是国民经略整理的一组数据，各大省份前三季度的GDP排名如下： | | 地区 | 2025Q3 | 2024Q3 | 增量 | 名义增速 | 实际增速 | 2024年 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 广东 | 105177 | 102187 | 2990 | 2.9% | 4.1% | 141634 | | 2 | 江苏 | 102811 | 99235 | 3576 | 3.6% | 5.4% | 137008 | | 3 | 山东 | 77115 | 73782 | 3333 | 4.5% | 5.6% | 98566 | | 4 | 浙江 | 68495 | ୧୧୦୧୨ | 3436 | 5.3% | 5.7% | 90131 | | 5 ...

党的二十届四中全会通过的《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》（以下 简称《建议》）深刻总结了"十四五"时期我国发展取得的重大成就，指出："我国经济实力、科技实 力、综合国力跃上新台阶，中国式现代化迈出新的坚实步伐，第二个百年奋斗目标新征程实现良好开 局。""十四五"时期的重大成就为谱写"十五五"时期经济社会发展新篇章奠定坚实基础。 一、"十四五"时期我国发展成就举世瞩目 第一，经济实力显著增强。我国经济总量持续增长，增速继续领跑全球主要经济体，预计2025年国内生 产总值达到140万亿元左右，人均国内生产总值超过世界平均水平，接近现行高收入国家水平。经济发 展质量持续提高，新质生产力稳步发展，全要素生产率稳步提升，全员劳动生产率年均增长6%。在全 球价值链各行业上下游十大关键节点中，我国主导的关键节点数量约占一半。我国仍然是世界经济增长 的主要动力源和重要引擎。 第二，科技创新成果丰硕。把科技自立自强作为国家发展的战略支撑，健全新型举国体制，加快布局国 家战略科技力量，创新实力持续提升，创新成果不断涌现。2024年全社会研发经费投入超过3.6万亿 元，基础研究经费占比达到6.88%，均 ...

Core Insights - The Hubei Ezhou Huahu International Airport, Asia's first dedicated cargo airport, has seen a significant increase in import and export express shipments, totaling 1.14 million items from January to October, representing a year-on-year increase of 254.2% [1] Group 1: Operational Efficiency - The airport's operations have been enhanced by a 52-kilometer intelligent sorting line that operates at a speed of 2.7 meters per second, capable of processing 280,000 express items per hour, with individual items sorted in as little as 5 minutes [2] - Ezhou Customs has innovated the sorting process by integrating international and domestic express operations, improving processing efficiency by 30% through a "front sorting and back mixing" model for imports and a "front mixing and back sorting" model for exports [2][3] Group 2: Strategic Developments - The establishment of the "Chilean Fruit Logistics Hub" at the airport marks it as a key entry point for Chilean fruits into China, enhancing the airport's role in global supply chains [2] - Ezhou Customs has implemented a "7×24 hours" green channel for fresh products, allowing for real-time document review and expedited customs clearance, significantly reducing transit times for perishable goods like Chilean cherries to major cities [3] Group 3: Growth Metrics - Since its opening over three years ago, the airport has executed more than 70,000 cargo flights and handled over 2.4 million tons of cargo, with 61 domestic and 50 international cargo routes, covering over 170 countries and regions [3]

Core Points - Inner Mongolia's total industrial added value is set to exceed 1 trillion yuan in 2024, marking a historic milestone [1] - The average annual growth rate of industrial added value is projected at 9.3%, contributing 38% to the GDP, an increase of 5.6 percentage points compared to the end of the 13th Five-Year Plan [1] - Inner Mongolia ranks 14th nationally in total industrial output, moving into the upper-middle tier of the country [1] Industrial Structure - The industrial sector in Inner Mongolia is primarily composed of energy and manufacturing, with over 90 industrial products leading in national production capacity [2] - The energy sector includes coal production, total power generation capacity, and renewable energy, with 15 energy products ranking first in the country [2] - Inner Mongolia is the first province to exceed 100 million kilowatts in renewable energy capacity [2] Manufacturing Sector - The manufacturing sector has established key industries such as metallurgy, chemicals, agricultural and livestock product processing, and modern equipment manufacturing, with an average annual growth rate of 10.1% during the 14th Five-Year Plan [2] - Manufacturing contributes over 50% to the industrial added value, serving as the main engine for industrial growth [2] - In the manufacturing sector, 76 products have the largest production capacity in the country, including 21 in chemicals, 14 in new materials, 4 in modern equipment, 18 in biomedicine, and 9 in agricultural processing [2] Policy and Development - During the 14th Five-Year Plan, Inner Mongolia has improved mechanisms for the coordinated development of traditional, emerging, and future industries [2] - Policies have been developed for key industries such as coking, rare earths, lithium, fluorine chemicals, and dairy, enhancing the support and adaptability of the industrial policy system [2] - The establishment of a key industry guidance fund and the implementation of low-altitude economy development plans are part of the efforts to strengthen and optimize key industries [2]

Core Viewpoint - The article emphasizes the acceleration of innovation in the pharmaceutical and medical device industries in China, driven by supportive policies and a shift from generic to innovative drug development, which is expected to enhance the industry's quality and global competitiveness [2][3][5]. Policy Support for Innovation - Since 2020, numerous favorable policies have been introduced to improve the ecosystem for innovative drugs, focusing on research standards, review and approval systems, patent protection, and reimbursement mechanisms [2]. - The "14th Five-Year Plan" highlights the importance of supporting innovative drugs and medical devices, indicating their critical role in national health and economic development [3][5]. Clinical Trials and Market Dynamics - The number of clinical trials for innovative drugs in China has surpassed 1,900, outpacing the US, Europe, and Japan, reflecting a significant increase in research quality and efficiency [3][8]. - By 2024, 39 innovative drugs approved for the first time in China were domestically developed, increasing from 31% in 2020 to 42% in 2024, indicating a strong trend towards domestic innovation [3][5]. Medical Insurance and Payment Systems - The narrowing surplus of the national medical insurance fund has created a mismatch between the commercialization of innovative drugs and their approval timelines, necessitating improvements in the commercial insurance system [8][27]. - The "15th Five-Year Plan" aims to establish a multi-tiered medical insurance system, which is expected to enhance the role of commercial health insurance in providing payment support for innovative drugs [27][32]. Medical Devices and Technological Innovation - The approval of innovative medical devices has increased by 43% from 2016-2020 to 2021-2024, driven by improved regulatory mechanisms and support for high-end medical device innovation [10][13]. - The article notes that while domestic brands are gaining global competitiveness, the industry still faces challenges in achieving systematic original innovation and key technology breakthroughs [13][19]. Emerging Technologies - The application of AI and brain-machine interfaces in healthcare is progressing towards industrialization, with the establishment of preliminary frameworks for clinical applications and payment rules [14][18]. - The integration of high-quality data flow in healthcare is anticipated to enhance the clinical benefits of new technologies, improving resource utilization and patient outcomes [18][19]. Biomanufacturing Developments - The biomanufacturing sector in China is transitioning from a "follower" to a "runner" stage, with significant advancements in technology and policy support, laying a solid foundation for future growth [19][20]. - The article highlights the importance of focusing on high-value, environmentally friendly products, such as biodegradable materials, to expand market opportunities [22][26].

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown a mixed performance in financing activities and stockholder dynamics, with a slight increase in revenue and net profit year-on-year, indicating stable growth in its core business segments [1][2][3] Financing Activities - On November 11, Baiyunshan's financing buy-in amounted to 21.89 million yuan, while financing repayment reached 35.18 million yuan, resulting in a net financing outflow of 13.30 million yuan [1] - The total financing and securities balance for Baiyunshan as of November 11 is 859 million yuan, with the financing balance accounting for 2.23% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, Baiyunshan repaid 1,000 shares and sold 11,000 shares on November 11, with the selling amount calculated at 301,100 yuan, and the remaining securities lending balance is 8.10 million shares [1] Company Overview - Baiyunshan Pharmaceutical Group, established on September 1, 1997, and listed on February 6, 2001, operates in various sectors including traditional Chinese medicine, chemical raw materials, and health management [2] - The company's revenue composition shows that the major commercial segment contributes 69.32%, followed by health products at 16.79%, and traditional medicine at 12.53% [2] - For the period from January to September 2025, Baiyunshan reported a revenue of 61.61 billion yuan, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, up by 4.78% [2] Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.91 billion yuan in dividends, with 4.36 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include China Securities Finance Corporation, holding 47.28 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 20.44 million shares [3] - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which have seen a decrease in their holdings compared to the previous period [3]

Core Insights - The regional economic landscape is undergoing a significant reshuffle, with key changes in the top 20 cities by GDP in China for 2023, highlighting the impact of national regional development strategies and cities seizing opportunities from new productivity transformations [1][10] Group 1: Shanghai - Shanghai has become the first city in China to surpass a GDP of 40 trillion yuan, showcasing its dual advantages as an international financial center and a hub for technological innovation [4][5] - The city's strategic emerging industries account for 42% of its total output, with leading sectors such as integrated circuits, biomedicine, and artificial intelligence exceeding a scale of 1.7 trillion yuan [4][5] - The logistics advantage is underscored by the Yangshan Deep-Water Port, which has maintained the highest container throughput globally for 13 consecutive years, positioning Shanghai as a key node in the dual circulation economic framework [5] Group 2: Hangzhou - Hangzhou leads the 20 strong cities with an impressive GDP growth rate of 11.08%, driven by its digital economy, which contributes over 50% to its core industries [7] - The establishment of Alibaba's global headquarters and the empowerment of over 8,000 tech SMEs by Ant Group highlight the city's unique platform economy ecosystem [7] - Manufacturing investment in Hangzhou has surged by 28.9%, with companies like Xinhua San Group achieving a 30% increase in production efficiency through digital technology integration [7] Group 3: Changsha - Changsha has surpassed Wuxi to rank 15th nationally, with its engineering machinery industry serving as a key growth driver, led by companies like SANY Heavy Industry and Zoomlion [9] - The city's industrial added value growth rate stands at 7.5%, exceeding the national average by 3.7 percentage points, indicating robust industrial performance [9] - The establishment of the Xiangjiang Science City is fostering the rapid development of emerging industries such as semiconductors and aerospace, signaling a shift from a single-industry focus to a diversified innovation matrix [9]

Group 1 - The eighth China International Import Expo (CIIE) in Shanghai has seen a significant number of investment and procurement projects signed, showcasing new collaborations and orders [1] - Shanghai state-owned enterprises signed 12 projects with a total transaction amount of approximately 2.99 billion yuan, reflecting an increase in procurement efforts across various sectors including bulk commodities, biomedicine, high-end equipment, and intelligent systems [2] - Since the first CIIE, Shanghai state-owned enterprises have organized 177,000 professional attendees and achieved a cumulative intended procurement amount of 22.2 billion USD with companies from over 20 countries and regions [2] Group 2 - The Shanghai Medical Security Bureau signed procurement intentions for selected drugs and high-value medical consumables, with a total intended procurement amount of approximately 2.07 billion yuan [4] - The procurement includes products from foreign enterprises that were selected in the national centralized procurement process, with companies like Sanofi and Abbott participating [4] - The city is exploring centralized procurement for high-value medical consumables, aiming to reduce medical costs for the public [4] Group 3 - The Hongkou division of the Shanghai trading group achieved a record high in procurement orders amounting to 1.88 billion USD, with significant contributions from companies like Shiseido and Panasonic [5] - The Jing'an district's procurement orders have consistently ranked first in the city for seven consecutive years, accounting for a quarter of the total procurement orders at this year's CIIE [5] - Major companies including Cargill, L'Oréal, and Calvin Klein signed procurement and cooperation agreements during the event [5] Group 4 - The Yangpu division of the Shanghai trading group reported a new high in intended transaction amounts, with notable procurement in food products and high-end consumer goods reflecting market consumption upgrades [6] - Strategic cooperation agreements were signed with companies like Synopsys and Amcor, indicating a focus on innovation and sustainable development in the industry [6]